Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGR-1505 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
Focus Adverse reactions
Sponsors Schrodinger

12 Jun 2025 According to a Schrodinger media release, the company to host a conference call on Thursday, June 12, 2025, at 8:00 a.m. ET to review the clinical opportunity for SGR-1505 and review the Phase 1 data presented at EHA.
12 Jun 2025 According to a Schrodinger media release, dose escalation is complete, and company is look forward to discussing these results and proposed recommended Phase 2 dose with the FDA later this year.
12 Jun 2025 According to a Schrodinger media release, data from this trial were presented in at the European Hematology Association Annual Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com